HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xiaqing Xu Selected Research

GSK2110183

4/2021Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xiaqing Xu Research Topics

Disease

6Neoplasms (Cancer)
04/2021 - 01/2018
2Hyperglycemia
01/2020 - 11/2018
1Stomach Neoplasms (Stomach Cancer)
04/2021
1Liver Neoplasms (Liver Cancer)
11/2018
1Neoplasm Metastasis (Metastasis)
01/2018
1Lung Neoplasms (Lung Cancer)
01/2018

Drug/Important Bio-Agent (IBA)

2B7-H1 AntigenIBA
01/2020 - 01/2019
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2020 - 11/2018
1GSK2110183IBA
04/2021
1Drug CombinationsIBA
04/2021
1Biological ProductsIBA
04/2021
1afuresertibIBA
04/2021
1ceritinibIBA
04/2021
1capivasertibIBA
04/2021
1AICA ribonucleotide (ZMP)IBA
11/2018
1Insulin (Novolin)FDA Link
11/2018
1Imatinib Mesylate (Gleevec)FDA Link
01/2018
1Conditioned Culture MediaIBA
01/2018

Therapy/Procedure

2Drug Therapy (Chemotherapy)
04/2021 - 11/2018
2Therapeutics
11/2018 - 01/2018